Document:

Exhibit

Exhibit 10.42
Confidential PTC draft – November 11, 2019

Certain identified information has been marked in the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed.

License and Technology Transfer Agreement Amendment No. 2
(“Amendment No. 2”)
Effective Date: Dec. 1, 2019
Parties to Agreement:
National Taiwan University        (“Party A”)
Professor Wuh-Liang (Paul) Hwu    (“Party B”)
PTC Therapeutics GT, Inc.        (“Party C”)

WHEREAS, Party A and Party B entered in to a certain License and Technology Transfer Agreement with Agilis BioTherapeutics, LLC, NTU Contract No.: 104-I0TC-10, dated December 23, 2015 (the “Agreement”);
WHEREAS, on February 4, 2017, Agilis BioTherapeutics, LLC, converted its corporate form and changed its name to Agilis BioTherapeutics Inc.; 
WHEREAS, on August 23, 2018, PTC Therapeutics, Inc. acquired Agilis BioTherapeutics, Inc., via its wholly-owned subsidiary PTC Therapeutics Holdings, Inc., and on August 24, 2018, changed its name to PTC Therapeutics GT, Inc.;
WHEREAS, PTC Therapeutics GT, Inc. (Party C) is now a wholly-owned affiliate of PTC Therapeutics, Inc. and the successor to all the rights and obligations of Agilis BioTherapeutics, LLC under the Agreement;
WHEREAS, Party C is pursuing a regulatory strategy of direct pursuit of marketing approval for the first Licensed Product, and therefore will not conduct a Phase III study;
WHEREAS, the Parties desire to amend the agreement to reflect this regulatory strategy and change the triggering event for payment of the former Phase III milestones;
NOW, THEREFORE, the Parties hereby agree as Follows:
		
	1.
	The first two sentences of Section 3.3 of the Agreement are deleted in their entirety.

		
	2.
	Section 5.2.2 of the Agreement is amended to read in its entirety as follows: 
 
“5.2.2    Upon the first to occur of (i) acceptance of filing of an NDA for Licensed Product by FDA or (ii) acceptance of filing of an MAA for Licensed Product by EMA, Party C shall pay Party A milestone of $[**] US.”

Confidential PTC draft – November 11, 2019

		
	3.
	Section 5.2.3 of the Agreement is amended to read in its entirety as follows: 
 
“5.2.3    (Intentionally omitted).”

[Signatures on Following Page]
Parties to License and Technology Transfer Agreement Amendment No. 2

Party A: National Taiwan University 
Representative:

By: /s/ Chung-Ming Kuan    12/10/2019
       (signature)    (date)

Party B: Professor Wuh-Liang (Paul) Hwu 

By: /s/ Wuh-Liang Hwu    11/25/2019
       (signature)    (date)

Party C: PTC Therapeutics GT, Inc. 
Representative:

By: /s/ Mark E. Boulding    12/10/2019
       (signature)    (date)Exhibit

Exhibit 10.51
Certain identified information has been marked in the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed.

FIRST AMENDMENT TO LEASE AGREEMENT

This First Amendment (“First Amendment”) to the Lease Agreement ( “Lease”) is made on this 7th day of October 2019 by and between BRISTOL-MYERS SQUIBB COMPANY, a Delaware corporation, having an office at 3551 Lawrenceville Princeton Road, Princeton, New Jersey 08540 (“Landlord”), and PTC THERAPEUTICS, INC., a Delaware Corporation, having an office at 100 Corporate Court, South Plainfield, NJ 07080-2449 (“Tenant”).
WHEREAS, Landlord and Tenant entered into a certain Lease dated August 3, 2019 pursuant to which Landlord agreed to lease to Tenant and Tenant agreed to lease from Landlord a portion of 311 Pennington Rocky Hill Road, Hopewell Township, Mercer County, New Jersey, designated in the Lease as the Premises and further described in Exhibit A to the Lease; and 
WHEREAS, Section 4.2(a)(iii) of the Lease defined the “CAM Area Operating Expenses” and, in connection with said definition, provided as follows:  
Landlord agrees that the Controllable CAM Expenses for the first calendar year of the Term, for which all future escalations of Controllable CAM Expenses shall be based, shall not exceed the lesser of (A) the actual Controllable CAM Expenses incurred by Landlord for such calendar year, and (B) an estimated amount per square foot to be determined by the parties pursuant to a certain side letter executed simultaneously herewith multiplied by [**] percent ([**]%) (even if the actual Controllable CAM Expenses for the first calendar year of the Term exceeds this figure).  
WHEREAS, pursuant to the portion of Lease Section 4.2(a)(iii) referenced in the prior “WHEREAS’ clause, Landlord and Tenant entered into a side letter dated August 3, 2019, a copy of which is attached to this First Amendment as Exhibit A (“Side Letter”), by which the parties agreed to a method of establishing the estimated amount per square foot of Controllable CAM Expenses for the first calendar year of the Term;
WHEREAS, Landlord and Tenant have complied with the terms of the Side Letter and have reach an agreement as to the estimated amount per square foot of Controllable CAM Expenses for the first calendar year of the Term and, by this First Amendment, amend the Lease to memorialize this figure.  
WHEREAS, at the time of the execution of the Lease, Tenant had not yet obtained an executed letter of credit (“LOC”) in connection with the Security Deposit requirement of the Lease set forth in Section 39 and a form of Letter of Credit was attached to the Lease as Exhibit P; and 
WHEREAS, Tenant has obtained and delivered to Landlord the signed LOC and, by this First Amendment, Landlord and Tenant agree to amend the Lease to incorporate the executed LOC as Exhibit P of the Lease; 
NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Landlord and Tenant agree to amend the Lease as follows:

1.The WHEREAS clauses set forth above are incorporated into this First Amendment by reference.  
2.The final sentence of Section 4.2(a)(iii) of the Lease is replaced as follows:  
Landlord agrees that the Controllable CAM Expenses for the first calendar year of the Term, for which all future escalations of Controllable CAM Expenses shall be based, shall not exceed the lesser of (A) the actual Controllable CAM Expenses incurred by Landlord for such calendar year, and (B) [**] per square foot ($[**]/square foot) (even if the actual Controllable CAM Expenses for the first calendar year of the Term exceeds this figure).  
3.    Landlord and Tenant agree that the figure of [**] per square foot ($[**]/square foot) is derived from the spreadsheet entitled “Princeton West Estimated CAM Costs” attached to this First Amendment as Exhibit B.  This figure represents the current estimated Controllable CAM Expenses as set forth on Exhibit B multiplied by [**] Percent ([**]%) to establish the estimated increase in the Controllable CAM Expenses between the date of the First Amendment and the anticipated Commencement Date of the Lease on July 1, 2020, further multiplied by [**] Percent ([**]%) as agreed by Landlord and Tenant in Section 4.2(a)(iii) of the Lease. 
4.    The LOC issued by HSBC Bank USA, N.A. to Bristol-Myers Squibb Company, as beneficiary on September 3, 2019 and the amendment to that LOC, also dated September 3, 2019, both attached to this First Amendment as Exhibit C, are collectively incorporated into and made a part of the Lease and that the first sentence of Section 39(a) of the Lease is amended to state that the executed LOC has been provided by Tenant.  
5.    This Amendment may be executed in one or more counterparts, which shall be deemed an original, and all of which together shall be deemed one and the same instrument.  A facsimile or pdf transmission of an original signature shall be deemed an original signature.  
6.    Except as modified hereby, all terms of the Lease remain in full force and effect.  In the event of a conflict between the terms of the Lease and this First Amendment, the terms of this First Amendment shall prevail.

[SIGNATURE PAGE TO FOLLOW]

IN WITNESS WHEREOF, Landlord and Tenant, intending to be legally bound, execute this First Amendment as of the dates set forth below.
LANDLORD:
BRISTOL-MYERS SQUIBB COMPANY, a Delaware corporation
                    
By:__/s/ Bruce K. Mayer_____________________
       Name:  Bruce K. Mayer
       Title:  Head Global Real Estate

TENANT:
  PTC THERAPEUTICS, INC., a Delaware corporation
By:__/s/ Mark Boulding_______________________
         Name:  Mark Boulding
Title:  Chief Legal Officer and Executive Vice PresidentExhibit

Exhibit 4.2

DESCRIPTION OF THE REGISTRANT'S SECURITIES
REGISTERED UNDER SECTION 12 OF THE
SECURITIES EXCHANGE ACT OF 1934

ASGN Incorporated (“ASGN”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) - our common stock, par value $0.01 per share (the “Common Stock”).  Our Common Stock trades on the New York Stock Exchange under the symbol “ASGN.”

Description of Common Stock

The following summary description sets forth some of the general terms and provisions of the Common Stock.  Because this is a summary description, it does not contain all of the information that may be important to you.  For a more detailed description of the Common Stock, you should refer to the provisions of our Restated Certification of Incorporation (the “Certificate of Incorporation”) and our Amended and Restated Bylaws (the “Bylaws”), each of which is an exhibit to the Annual Report on Form 10-K to which this description is an exhibit.

General

Under the Certificate of Incorporation, ASGN is authorized to issue 76,000,000 shares of stock, consisting of 75,000,000 shares of Common Stock, par value $0.01 per share (“Common Stock”), and 1,000,000 of preferred stock, par value $0.01 per share (the “Preferred Stock”).  No shares of any Preferred Stock are currently issued and outstanding.   The Board of Directors has the authority to alter, amend or repeal the Bylaws, subject to certain limitations set forth in the Bylaws.

No Preemptive, Redemption or Conversion Rights

Holders of shares of Common Stock have no preemptive rights to maintain their percentage of ownership in future offerings or sales of stock of ASGN.  The Common Stock is not redeemable, is not subject to sinking fund provisions, does not have any conversion rights and is not subject to call.

Voting Rights

Holders of shares of Common Stock have one vote per share in all elections of directors and on all other matters submitted to a vote of stockholders of ASGN.  Holders of shares of Common Stock do not have cumulative voting rights.

Dividend Rights

Subject to the prior rights of holders of all classes of stock at the time outstanding having prior rights as to dividends, the holders of Common Stock are entitled to receive dividends, if any, as and when declared, from time to time, by our Board of Directors out of funds legally available therefor.  

1

Board of Directors

ASGN has a classified Board of Directors.   The directors are classified, with respect to the time for which they severally hold office, into three classes: Class I, Class II and Class III.  Each class consists, as nearly as possible, of one-third of the whole number of directors.   Our Bylaws establish that the size of the whole Board of Directors shall consist of not less than four members and not more than nine members, with the exact number of directors to be fixed from time to time within such range by a duly adopted resolution of the Board of Directors.  At each Annual Meeting of Stockholders, the directors of the expiring class are elected to hold office for a term to expire at the third Annual Meeting of Stockholders after their election, or until his or her earlier resignation or removal, and until their respective successors are duly elected and qualified.   The alteration, amendment or repeal of the classified Board requires an amendment to the Bylaws and the Certificate of Incorporation.  To amend the classified Board provision of the Certificate of Incorporation requires the affirmative vote of not less than a majority of the then outstanding shares of capital stock entitled to vote generally in an election of directors.

Action by Stockholder Consent 

Any action required or permitted to be taken at any annual or special meeting of the stockholders may be taken without a meeting, without prior notice and without a vote, if a consent or consents in writing or by electronic transmission, setting for the action so taken, shall be signed by the holders of outstanding stock having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to vote thereon were present and voted and shall be delivered to the Corporation by delivery to its registered office in the State of Delaware, its principal place of business, or an officer or agent of the Corporation having custody of the book in which minutes of proceedings of stockholders are recorded. 

Power to Call Special Stockholder Meeting

Under Delaware law, a special meeting of stockholders may be called by our Board of Directors or by any other person authorized to do so in the Certificate of Incorporation or Bylaws.  Pursuant to our Bylaws, a special meeting of the stockholders may be called by the President or the Chairman of the Board only at the request in writing of a majority of the Board of Directors, or at the request in writing of stockholders owning at least 25% of the voting power of the entire voting stock of the Corporation issued and outstanding. Such request shall state the purpose or purposes of the proposed meeting. 

Liquidation, Dissolution or Similar Rights

Subject to the prior rights of holders of all classes of stock at the time outstanding having prior rights as to liquidation, upon the liquidation, dissolution or winding up of the Corporation, the assets of the Corporation shall be distributed to the holders of the Common Stock. 

2

Forum Selection Clause

Under our Certificate of Incorporation, unless ASGN consents in writing to the selection of an alternative forum, the sole and exclusive forum for making certain types of claims shall be the Court of Chancery of the State of Delaware.  This provision applies to (1) any derivative action or proceeding brought on behalf of ASGN, (2) any action asserting a claim of breach of fiduciary duty owed by any director, officer, employee or agent of ASGN to ASGN or ASGN’s stockholders, (3) any action asserting a claim arising pursuant to any provision of the General Corporation Law of Delaware, the Certificate of Incorporation or Bylaws, (4) any action to interpret, apply, enforce or determine the validity of the Certificate of Incorporation or the Bylaws, or (5) any action asserting a claim governed by the internal affairs doctrine, in each case subject to the Delaware Court of Chancery having personal jurisdiction over the indispensable parties named therein.

3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00305-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00305-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00305-of-00352.parquet"}]]